Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

Key Points

• Xencor hit a new 52-week high, trading as high as $20.26 before settling at $18.81, reflecting strong recent momentum in the stock.
• Analyst opinions are mixed but lean positive overall: the stock carries an average Moderate Buy rating with a consensus price target of $24.25, though some firms recently downgraded or maintained sell ratings.
• The company’s latest earnings were weak, with a quarterly EPS miss and revenue far below expectations, underscoring that the share-price strength is coming despite continued fundamental challenges.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.26 and last traded at $18.81, with a volume of 2862329 shares traded. The stock had previously closed at $17.47.

Analysts Set New Price Targets

XNCR has been the topic of a number of recent analyst reports. Wall Street Zen lowered Xencor from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 9th. Truist Financial decreased their price target on Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price target on Xencor from $13.00 to $14.00 and gave the stock a "neutral" rating in a research note on Monday, May 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Zacks Research raised shares of Xencor from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $24.25.

Xencor Stock Performance

The firm's 50 day simple moving average is $13.33 and its 200-day simple moving average is $12.80. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -8.21 and a beta of 0.86.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. During the same period last year, the business earned ($0.66) EPS. The business's quarterly revenue was down 86.2% on a year-over-year basis. As a group, equities analysts anticipate that Xencor, Inc. will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently bought and sold shares of XNCR. AQR Capital Management LLC acquired a new position in shares of Xencor in the 1st quarter valued at about $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xencor by 9.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock worth $471,000 after purchasing an additional 3,692 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Xencor by 89.9% during the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock worth $7,732,000 after purchasing an additional 344,088 shares during the period. Creative Planning grew its position in Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company's stock valued at $143,000 after purchasing an additional 3,661 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Xencor by 170.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company's stock valued at $2,594,000 after buying an additional 208,182 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.